Incident coronary heart disease after Preeclampsia: Role of reduced fetal growth, preterm delivery, and parity by Riise, Hilde Kristin Refvik et al.
Incident Coronary Heart Disease After Preeclampsia: Role of Reduced
Fetal Growth, Preterm Delivery, and Parity
Hilde Kristin Refvik Riise, MSN; Gerhard Sulo, MD, PhD; Grethe S. Tell, MPH, PhD; Jannicke Igland, PhD; Ottar Nygard, MD, PhD;
Stein Emil Vollset, MD, DrPH; Ann-Charlotte Iversen, PhD; Rigmor Austgulen, MD, PhD; Anne Kjersti Daltveit, PhD
Background-—Preeclampsia is a severe pregnancy disorder often complicated by reduced fetal growth or preterm delivery and is
associated with long-term maternal morbidity and mortality. We aimed to assess the association between preeclampsia
phenotypes and risk of subsequent coronary heart disease and maternal cardiovascular mortality.
Methods and Results-—Women aged 16 to 49 years who gave birth during 1980–2002 and registered in the Medical Birth
Registry of Norway were followed prospectively (1–29 years) for an incident major coronary event and mortality through linkage
with the Cardiovascular Disease in Norway 1994–2009 (CVDNOR) project and the Norwegian Cause of Death Registry.
Preeclampsia was subdivided based on the presence of a child born small for gestational age or preterm delivery. Among 506 350
women with 1 to 5 singleton births, there were 1275 (0.3%) occurrences of major coronary event, 468 (0.1%) cardiovascular
deaths, and 5411 (1.1%) deaths overall. Compared with women without preeclampsia, the hazard ratio (95% CI) for major coronary
event was 2.1 (1.73–2.65) after preeclampsia alone, 3.3 (2.37–4.57) after preeclampsia in combination with small for gestational
age, and 5.4 (3.74–7.74) after preeclampsia in combination with preterm delivery. Analyses distinguishing women with 1
(n=61 352) or >1 (n=281 069) lifetime pregnancy and analyses with cardiovascular mortality as outcome followed the same
pattern.
Conclusions-—The occurrence of major coronary events was increased among women with preeclampsia and highest for
preeclampsia combined with a child born small for gestational age and/or preterm delivery. ( J Am Heart Assoc. 2017;6:
e004158. DOI: 10.1161/JAHA.116.004158.)
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P reeclampsia is a hypertensive pregnancy disorder that isassociated with increased morbidity and mortality for
both mother and child.1 Preeclampsia manifests as hyperten-
sion and proteinuria in the latter half of 2% to 8% of all
pregnancies, and is more prevalent in the first pregnancy.2 No
optimal predictive test or efficient treatment for preeclampsia
exists. Development of preeclampsia often starts in early
pregnancy with reduced remodeling of the uterine spiral
arteries and formation of atherosclerosis-like lesions, and the
resulting disturbed blood flow leads to formation of a damaged
placenta.3 The dysfunctional placenta becomes a stressed
organ characterized by oxidative stress and inflammation as
the fetus grows and demands a fully functional placenta.4
Eventually, the release of antiangiogenic and inflammatory
factors to the maternal circulation becomes too high a burden
and the mother develops systemic inflammation with endothe-
lial dysfunction, thrombophilia, and impaired hemodynam-
ics.5,6 Similar processes also characterize development of
coronary heart disease.7 A close connection between devel-
opment of preeclampsia and later cardiovascular disease
(CVD) has become apparent in recent years,8 but how these
vascular diseases are connected is still not clear.
In addition to being a heterogeneous disorder with clinical
signs ranging from mild to life-threatening, preeclampsia is
often interrelated with adverse pregnancy outcomes such as
reduced fetal growth and preterm delivery, with partly shared
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underlying pathogenic mechanisms and risk factors.9,10 These
complications are all independent risk factors for subsequent
maternal CVD.11–13 For improved insight into the relationship
between preeclampsia and CVD, a broader look at related
pregnancy complications and CVD should be undertaken. We
have identified 3 studies in which the relationship between
preeclampsia, reduced fetal growth, preterm delivery, and
subsequent cardiovascular morbidity risk has been investi-
gated.14–16 Preeclampsia and gestational hypertension were
shown to be associated with subsequent development of
ischemic heart disease, and the risk was highest for
preeclampsia combined with reduced fetal growth and/or
preterm delivery. However, these studies: (1) did not focus on
acute coronary events but did include stable angina pectoris;
(2) covered a limited time span following pregnancy; (3) did
not fully assess parity; and (4) examined smaller cohorts
(2 studies15,16).
By linking data from the Medical Birth Registry of Norway
(MBRN) to the nationwide Cardiovascular Disease in Norway
1994–2009 (CVDNOR) project (www.cvdnor.no) containing
data on all CVD hospitalizations and deaths, we aimed to
examine whether preeclampsia alone or combined with
reduced fetal growth and/or preterm delivery increases the
risk of subsequent major coronary events (MACEs) and
cardiovascular mortality. In addition, we wanted to examine




Information on 708 614 women aged 16 to 49 years at
childbirth with a first birth registered in the MBRN during
1980–2009 was obtained. MBRN is a nationwide mandatory
registry containing information on all pregnancies above
16 weeks’ gestation in Norway since 1967. Data from the
antenatal forms are transferred to the MBRN after delivery.
The MBRN provides data for epidemiological surveillance of
maternal health, pregnancy complications, birth defects, and
other perinatal outcomes, and for research on their causes
and consequences.17
To follow women prospectively for MACE, we linked the
MBRN to the CVDNOR project, the Norwegian Cause of Death
Registry, Statistics Norway, and the National Population
Registry, from January 1980 through December 2009. The
CVDNOR project contains information on all hospitalizations
from all somatic hospitals in Norway with a CVD or diabetes-
related discharge diagnosis from 1994 to 2009.18 Underlying
cause and date of death were obtained from the Norwegian
Cause of Death Registry. From Statistics Norway and
the National Population Registry, information on
sociodemographic status, date of death, and date of emigra-
tion were extracted.
Exclusions
In order to have at least 7 years of observation time after a
woman’s first childbirth, to look for subsequent deliveries,
women with their first birth after 2002 were excluded
(170 392), leaving 538 222 women. Women with any births
before gestational week 20 (n=2980) were excluded, since
preeclampsia is diagnosed after 20 weeks of gestation. Based
on diagnosis in theMBRN or the CVDNOR project, 6333women
with existing heart disease at first delivery were excluded
(International Classification of Diseases, Tenth Revision [ICD-
10]: I01, I03–09, I11, I13, I20–25, I30–52 [and corresponding
for ICD-8 and ICD-9]). Womenwith babies with a z score outside
(4 +4) of birthweight by gestational week (n=3331) or missing
data on small for gestational age (SGA) and/or preterm delivery
in the same pregnancy as the first incidence of preeclampsia
(n=2428) were excluded. Women with any multiple gestation
were excluded from the analyses (n=16 784). Sixteen women
with negative follow-up time probably due to an erroneous date
of death were also excluded. This left us with 506 350 women
for the overall analyses (where parity was not considered)
(Figure 1). During the study period, 23 472 (4.6%) women
emigrated. We conducted additional analyses where we
excluded women with a diagnosis of diabetes (defined as type
1, type 2, or unspecified diabetes) before her first pregnancy
(n=1727), since diabetes is strongly associated with
preeclampsia, preterm birth,19 and coronary heart disease.20
In parity-specific analyses, we classified women as having
1 or >1 lifetime pregnancy by the age of 40 years and
analyzed the association between preeclampsia and MACE
separately. This age cutoff was chosen based on the
observation that the majority of women had completed their
reproductive career by that age, thus avoiding classifying a
woman’s number of lifetime pregnancies before she has
completed her reproductive career, ie, avoiding immortal time
bias. Women younger than 40 years at emigration, death,
time of MACE, or end of follow-up (December 31, 2009) were
excluded from analyses (n=163 929). This left us with
342 421 women, of whom 61 352 had 1 birth and
281 069 had >1 lifetime birth. Because preeclampsia is
related to the pregnancy, we also use the terms “one lifetime
pregnancy” and “more than one lifetime pregnancy,” although
the woman may have experienced pregnancies ending in an
abortion and hence was not reported in the birth registry.
Study Exposure and End Points
The MBRN defines preeclampsia as maternal blood pressure
of at least 140 mm Hg systolic or 90 mm Hg diastolic, or an
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increase of >15 mm Hg in blood pressure measured before
gestational week 20, in combination with proteinuria (protein
excretion >0.3 g per 24 hours or >+1 on dipstick). These
criteria are in accordance with the recommendations of the
American College of Obstetricians and Gynecologists.21 The
diagnostic validity of preeclampsia in the MBRN is high.22 A
broad phenotype was investigated with preeclampsia in the
presence or absence of a child born SGA and delivery before
or after 36 completed weeks of gestation (<37 or
≥37 weeks). SGA was defined as fetal growth <10th
percentile of Norwegian birth weight curves.23 A composite
exposure variable was generated on the presence of
preeclampsia alone or in combination with a child born SGA
and/or preterm delivery. Mothers without preeclampsia in any
pregnancy served as the reference group. We conducted
additional analyses applying more restrictive cutoffs for
preterm delivery (<34 weeks) and SGA (<7.5th percentile of
Norwegian birth weight curves).
The MACE (main end point) was defined as nonfatal acute
myocardial infarction (ICD-9: 410 or ICD-10: I21, I22) or
coronary death (ICD-9: 410–414 or ICD-10: I20–I25).
Secondary end points included CVD (ICD-9: 390–9; ICD-10:
I00–I99) and all-cause mortality.
In the analyses stratified by parity, we assessed whether
exposure-outcome associations differed according to a
woman’s lifetime number of births. Women with >1 lifetime
birth were stratified into: (1) no preeclampsia at all; (2)
preeclampsia in first pregnancy only; (3) preeclampsia in first
and second pregnancy; and (4) preeclampsia in second or
later but not first pregnancy.
Informed consent was waived because data were collected
from national registries. The study was approved by the
Regional Committee for Medical and Health Research Ethics
(2014/1047).
Statistical Methods
Data were analyzed by Cox proportional hazard regression on
two sets of analyses: (1) all pregnancies starting follow-up at
first birth; and (2) parity-specific analyses starting follow-up at
age 40. The level of significance was defined as <0.05 in all
analyses.
In the overall analysis (n=506 350), associations between
exposure categories and all 3 end points were examined using
maternal age as the time scale in both Cox regression and in
Kaplan–Meier curves. Follow-up time was calculated as the
difference between age at the date of hospital admission,
death, emigration or December 31, 2009 (whichever occurred
first), and age at first birth. In these analyses, we compared
the risk of MACE among women with and without
Figure 1. Flow diagram of number of study patients. Data on 708 614 women with a first birth registered
in the Medical Birth Registry of Norway during 1980–2009 were available. MACE indicates major coronary
event; PE, preeclampsia; preterm delivery, <37 weeks of gestation; SGA, small for gestational age (<10th
percentile).
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preeclampsia at the same age. Because preeclampsia could
occur in any pregnancy, preeclampsia was introduced in the
model as a time-dependent covariate. This was done to avoid
classifying the mother as exposed while still unexposed, ie,
avoiding immortal time bias.24 By using age as a time-scale
and preeclampsia as a time-dependent covariate we account
for the age at which the woman has her first occurrence of
preeclampsia, and the age at which the woman has her first
MACE.
In the parity-specific analyses (n=342 421) in-depth anal-
yses with age as the time scale were done with MACE as the
end point and age 40 as the start of follow-up. Follow-up time
was calculated as the difference between age at the date of
hospital admission, death, emigration or December 31, 2009
(whichever occurred first), and age 40. Because 40 years of
age was used as the start of follow-up and preeclampsia
exposure was defined retrospectively, women with no
preeclampsia before age 40 were treated as unexposed in
the Cox regression analyses even if they developed the
syndrome after age 40 (n=405). The results of additional
analyses reclassifying these women as “exposed” at the time
of preeclampsia yielded similar results to those reported here.
For all analyses, potential confounders were evaluated and
chosen based on their association with the exposure and end
points. Education was classified into 3 categories: basic
education (compulsory education), upper secondary education
(high school or vocational school), and tertiary education
(college or university). Birth year of the first child independent
of significance level was included in the model to account for
potential cohort effects. Exclusion of women with chronic
renal disease before pregnancy (n=8905 [1.8%] in the overall
analyses) did not alter the hazard ratios (HRs), and women
with chronic renal disease were thus included in all presented
analyses. Two-way interaction terms for all combinations of
preeclampsia, education, marital status, and birth year of first
child were added in the multiple Cox regression analyses. No
significant interactions were found and results are based on
models without interaction terms.
Results
Characteristics of the Study Population
The characteristics of the 506 350 women in the total study
population stratified by parity and preeclampsia diagnosis are
shown in Table 1. Information on maternal age and year of
birth was complete. Information on maternal education was
missing in 1.0% of the women. Gestational week was missing
in 1 or more pregnancies in 6.5% of the women. Less than
0.2% of the women had missing values on the baby’s birth
weight in any pregnancy. Women with missing data were
excluded from all analyses.
The majority of the mothers had >1 lifetime birth (82.1%).
Women with only 1 lifetime birth were less likely to be
married/cohabitants, were older at the time of giving birth,
and had lower education and a higher prevalence of
prepregnancy diabetes.
Among the 29 917 (5.9%) women who had preeclampsia in
at least 1 pregnancy, 21 635 (72.3%) had a preeclamptic first
pregnancy. A preeclamptic first pregnancy occurred among
4385 (4.8%) women with only 1 lifetime birth and among
17 250 (4.1%) women with >1 lifetime birth. Preeclamptic
women were twice as likely to have a child born SGA (13.3%
versus 27.8% for women with 1 lifetime pregnancy and 16.8%
versus 29.9% for women with >1 lifetime pregnancy) and 3
times more likely to deliver preterm (6.1% versus 24.6% for
women with one lifetime pregnancy and 9.2% versus 25.4% for
women with >1 lifetime pregnancy) compared with women
without preeclampsia (Table 1).
During follow-up, 1275 (0.3%) women experienced MACEs
and 468 (0.1%) mothers died due to CVD and 5411 (1.1%) due
to any cause.
Preeclampsia and Risk of Subsequent MACE
The Kaplan–Meier curve shows the difference in survival
between women without preeclampsia compared with those
with preeclampsia only, preeclampsia combined with SGA,
preterm delivery, or both (P<0.001) (Figure 2).
The associations between preeclampsia and subsequent
MACEs and cardiovascular mortality are shown in Table 2.
Women who experienced preeclampsia alone showed a
doubled risk for subsequent MACEs compared with women
without preeclampsia, and this increased risk remained
statistically significant after adjusting for potential con-
founders (HR, 2.1; 95% CI, 1.73–2.65). Women with
preeclampsia combined with SGA and/or preterm delivery
showed a further doubled risk of MACEs (HR, 4.3; 95% CI,
2.81–6.43) compared with women with preeclampsia only.
The risk for MACE was highest for women with preeclampsia
in combination with preterm delivery (HR, 5.38; 95% CI, 3.74–
7.74) (Table 2).
Results from analyses stratified by parity are summarized
in Table 3. Among women with only 1 lifetime birth, having
preeclampsia only or preeclampsia with SGA and/or preterm
delivery increased the risk of subsequent MACEs 2 or 3 times,
respectively, compared with women without preeclampsia.
Among women with >1 lifetime birth, the risk of MACEs
after preeclampsia in the first pregnancy only, was 2.0-fold
(95% CI, 1.31–2.91) for preeclampsia alone and 2.8-fold (95%
CI, 1.70–4.61) for preeclampsia with SGA and/or preterm
delivery (Table 3). For women with recurrent preeclampsia the
presence of preeclampsia alone doubled the risk of MACE
(HR, 2.2; 95% CI, 0.91–5.32) and when combined with SGA
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and/or preterm delivery the risk was markedly higher at 4.7-
fold (95% CI, 2.31–9.37) compared with women without
preeclampsia (Table 3). We tested for interaction between
preeclampsia and mode of delivery by doing a likelihood ratio
test comparing models with and without an interaction term
and found no significant interaction; the association between
preeclampsia and MACEs does not vary by mode of delivery
(P=0.127).
Among women who did not experience preeclampsia,
women with 1 lifetime pregnancy had a higher risk of MACEs
compared with women with >1 lifetime pregnancy (HR, 1.3;
95% CI, 1.11–1.51).
The difference between analysis with and without diabetes
was most pronounced for MACEs after preeclampsia in
combination with preterm delivery, where the number of
MACEs declined from 30 to 20 and HR declined from 5.4 (95%
CI, 3.74–7.74) to 3.9 (95% CI, 2.51–6.09) (Table S1).
We repeated the analyses, applying a cutoff of 34 weeks for
preterm delivery and <7.5th percentile for SGA offspring and
this suggested stronger associations between MACEs and
preeclampsia in combination with SGA and/or preterm deliv-
ery. For preeclampsia+preterm delivery, HR increased from 5.4
(95% CI, 3.74–7.74) to 7.0 (95% CI, 4.18–11.5) (Table S2).
Preeclampsia and Risk of Cardiovascular and All-
Cause Mortality
Women with only preeclampsia showed an increased risk of
CVD mortality (HR, 1.6; 95% CI, 1.08–2.38) compared with
women without preeclampsia (Table 2). Mortality further
increased in women with preeclampsia combined with a child
born SGA (HR, 3.7; 95% CI, 2.26–6.13) or preterm delivery
(HR, 2.8; 95% CI, 1.25–6.29).
Women with only preeclampsia did not show increased all-
cause mortality, but for preeclamptic women with a SGA
offspring and preterm delivery, the risk of dying was 21% to
23% higher than that in women without preeclampsia;
however, these results were statistically nonsignificant.
Table 1. Characteristics of 506 350 Norwegian Women With 1 to 5 Singleton Deliveries and a First Delivery During 1980–2002,
by Parity and Presence of Preeclampsia
Characteristics of the Study Participants









Age at first birth, mean (SD), y 27.5 (5.7) 28.1 (5.6) 25.1 (4.2) 25.0 (4.2)
Education level, No. (%)†
Basic education 30 727 (35.7) 1661 (37.9) 113 396 (29.1) 7531 (29.5)
Secondary education 24 162 (28.0) 1329 (30.3) 118 591 (30.4) 7998 (31.3)
Tertiary education 28 747 (33.4) 1333 (30.4) 155 756 (39.9) 9877 (38.7)
Marital status at first birth, No. (%)‡
Married/cohabitant 62 303 (72.3) 3419 (78.0) 325 468 (83.4) 64 785 (16.6)
Other 23 877 (27.7) 966 (22.0) 21 525 (84.3) 4007 (15.7)
Diabetes mellitus, No. (%)§ 401 (0.5) 117 (2.7) 944 (0.2) 265 (1.0)
Preterm delivery, No. (%)k 5292 (6.1) 1080 (24.6) 35 714 (9.2) 6485 (25.4)
Small for gestational age, No. (%)¶ 11 487 (13.3) 1221 (27.8) 65 691 (16.8) 7631 (29.9)
Study end points, No. (%)
Major coronary event 352 (0.4) 55 (1.3) 743 (0.2) 125 (0.5)
Cardiovascular deaths 171 (0.2) 21 (0.5) 256 (0.1) 20 (0.1)
All deaths 2034 (2.4) 109 (2.5) 3065 (0.8) 203 (0.6)
Follow-up time until major coronary event,
median (IQR), y
17.2 (11.3) 15.9 (11.7) 18.5 (10.8) 17.8 (11.0)
Follow-up time until cardiovascular death, median
(IQR), y
17.2 (11.3) 15.7 (11.6) 18.5 (10.8) 17.8 (11.0)
IQR indicates interquartile range.
*In at least 1 of the pregnancies.
†Information on education was not available in 5242 (1.04%) of women .
‡Information on cohabitant only available from 1982.
§Diabetes mellitus diagnosed before the first pregnancy.
kLess than 37 weeks of gestation.
¶Lower than the 10th percentile.
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In this large register-based study, an association was found
between preeclampsia and subsequent risk of MACE and
cardiovascular mortality. The risk of MACE and cardiovascular
mortality was further markedly increased when preeclampsia
was combined with a child born SGA and/or preterm delivery,
and the highest risk was found for preeclamptic women with
preterm delivery. In parity analyses, the highest risk of MACE
was found for women with recurrent preeclampsia combined
with an SGA offspring and/or preterm delivery.
Preeclampsia and Subsequent Risk of MACE
Our findings are in line with previous studies linking
preeclampsia with subsequent ischemic heart disease.14–16
It is unclear what leads to this increased risk of MACEs, and
several hypotheses have been suggested.1,8 Women may
have a shared unfavorable cardiovascular and preeclampsia
risk profile before pregnancy involving risk factors such as
obesity, hypertension, high blood lipids, diabetes, and
physical inactivity.2 Women may have pleiotropic genetic
risk factors that predispose them to develop preeclampsia in
pregnancy and CVD later in life.3,25 The relationship may at
least partly be due to conditions in pregnancy since vascular
load of pregnancy complications, such as preeclampsia, may
create a maternal permanent metabolic or vascular imbal-
ance ultimately resulting in cardiovascular complications.
Women undergo major changes in cardiovascular function
during pregnancy.26 CVD is a result of a complex interplay of
multiple factors that span the life course,27 and pathways
leading to preeclampsia may share common physiologic
processes with the development of CVD and MACEs, such as
dyslipidemia.
Preeclampsia in Combination With a Child Born
SGA and/or Preterm Delivery
Pregnancy with an SGA offspring and/or preterm delivery
further increased the risk of MACEs in women with
preeclampsia. Severity of preeclampsia has been shown to
be associated with an increased risk of coronary heart
disease, although with lower magnitude than for preeclampsia
combined with an SGA offspring and/or preterm delivery.14
Early development of preeclampsia may lead to preterm
delivery, and this form of preeclampsia may have different
causes, severity, and outcome compared with preeclampsia
manifesting at gestation. The heterogeneous nature of
preeclampsia includes individual components of the initial
placental disease and of later maternal response to insuffi-
cient placentation or even to pregnancy itself, and presence
of an SGA offspring may reflect a more severe placental
disease of the syndrome.28 Such differences between
preeclampsia phenotypes were also apparent from the
findings that preeclampsia with a child born SGA was more
strongly associated with cardiovascular mortality, while
preeclampsia with preterm delivery was more strongly
associated with MACEs in our study.
Figure 2. Kaplan–Meier curves of subsequent risk of major coronary events (MACEs) according to
preeclampsia (PE) status (P<0.001). A total of 506 350 women aged 16 to 49 years were included and
1275 MACEs (0.3%) were registered. Preterm delivery indicates <37 weeks of gestation; SGA, small for
gestational age (<10th percentile).
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The relationship between parity and risk of coronary heart
disease in women has been assessed in previous studies.29 A
study from Norway focused on preeclampsia and the risk of
cardiovascular mortality comparing women with 1 lifetime
pregnancy and women with >1 lifetime pregnancy.30 The
authors of this study reported the highest cardiovascular
mortality risk after preeclampsia in women with only 1 lifetime
pregnancy. They also reported a strong effect on cardiovas-
cular mortality of having only 1 child among women without
preeclampsia (HR, 2.0). While we found the same HR for
mortality (2.1), the HR for MACE was only 1.3. Furthermore,
the increase in risk after preeclampsia was similar for women
with 1 lifetime pregnancy and women with >1 lifetime
pregnancy. In our study, the highest risk for MACEs was found
for women with recurrent preeclampsia complicating the first
2 pregnancies. This is in accordance with the risk for ischemic
heart disease after recurrent preeclampsia in a Danish14 and a
Swedish study.16 Several preeclamptic pregnancies might
increase the burden on the cardiovascular system and add to
a woman’s risk of later CVD.7,31,32
Strengths and Limitations
The strengths of this study include the large nationwide
cohort and historical observation of incident cardiovascular
events, both fatal and nonfatal. Prevalence of preeclampsia in
a woman’s first pregnancy has previously been reported to be
around 3.6% in Norway,33 compared with 4.3 in our study.
Reproductive history and information on both parity and
gestational age were available and loss to follow-up was
minimal.
Before 1999, only information on pregnancies lasting
≥16 weeks was included in the MBRN. Hence, we cannot
account for potential effects of early abortions. Early medical
interruptions of normal pregnancies may reduce the risk of
preeclampsia in a subsequent pregnancy due to immunolog-
ical changes, while spontaneous abortions can, to a larger
extent, be associated with other factors, such as infertility,
that may increase the risk of preeclampsia.34 Data on
subclassification of preeclampsia (mild, severe, unspecified)
were only available after 1999 in the MBRN, and instead of
subclassifying preeclampsia, a broader approach of address-
ing the related disorders reduced fetal growth and preterm
delivery was chosen to strengthen the study. Inclusion of
deliveries from 1980 to 1993 gave up to 14 years without
morbidity follow-up. However, the majority of coronary events
occur after age 50 and the median age at first delivery was
25.5 years. For women with first deliveries in 1994, only 4
had incident coronary events the following 10 years and 21
events were registered 10 to 14 years after delivery. Few CVD
events are therefore expected before 1994 for women with
first deliveries during 1980–1993 and full follow-up on deaths
Table 2. Preeclampsia and Subsequent Risk of Major Coronary Events and Cardiovascular Mortality Among 506 350 Norwegian
Women With 1 to 5 Singleton Deliveries and a First Delivery During 1980–2002
Study End Points No./Events
Unadjusted Adjusted*
HR (95% CI) P Value HR (95% CI) P Value
Major coronary event
No preeclampsia 476 506/1095 1  1 
Preeclampsia only 19 617/90 2.17 (1.75–2.69) <0.001 2.14 (1.73–2.65) <0.001
Preeclampsia+SGA and/or preterm delivery† 10 227/90 4.18 (3.37–5.18) <0.001 4.05 (3.27–5.02) <0.001
Preeclampsia+SGA 4495/37 3.49 (2.51–4.84) <0.001 3.30 (2.37–4.57) <0.001
Preeclampsia+preterm delivery 3266/30 5.25 (3.65–7.55) <0.001 5.38 (3.74–7.74) <0.001
Preeclampsia+SGA+preterm delivery 2466/23 4.42 (2.93–6.68) <0.001 4.25 (2.81–6.43) <0.001
Cardiovascular mortality
No preeclampsia 476 506/427 1  1 
Preeclampsia only 19 617/26 1.62 (1.09–2.41) 0.017 1.60 (1.08–2.38) 0.020
Preeclampsia+SGA and/or preterm delivery 10 227/26 3.13 (1.09–2.41) <0.001 3.06 (2.06–4.54) <0.001
Preeclampsia+SGA 4495/16 3.97 (2.41–6.54) <0.001 3.72 (2.26–6.13) <0.001
Preeclampsia+preterm delivery 3266/6 2.64 (1.18–5.91) 0.018 2.81 (1.25–6.29) 0.012
Preeclampsia+SGA+preterm delivery 2466/4 2.00 (0.75–5.35) 0.168 1.93 (0.72–5.16) 0.191
Cox regression analysis with preeclampsia as a time-dependent covariate. HR indicates hazard ratio; SGA, small for gestational age (<10th percentile).
*Analyses adjusted for education, marital status, and birth year of first child.
†<37 weeks of gestation.
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and serious CVD events were available in this period.
Exclusion of women younger than 40 years in the second
set of analyses might have introduced selection bias because
we restricted the analyses to a population older than 40 years
without any MACEs before the age of 40. We calculated that
the annual incidence of acute myocardial infarction among
women aged 25 to 39 years in Norway between 2001–2009
was low (from 11 to 15 per 100 000 persons per year).
Hence, the exclusion of these events was unlikely to
substantially influence our findings. Since our study was not
designed to analyze time trends in morbidity, we were not
able to determine whether time trends in CVD risk in affected
women differed from those in unaffected women. The data
from our study are from a period where preventive measures
based on risk assessment of women with preeclampsia were
not initiated in Norway, and few preeclamptic women in our
cohort were offered follow-up to assess CVD risk and reduce
morbidity. Information on underlying CVD risk factors such as
smoking and body mass index is missing in MBRN before
1998 because of a lack of registered lifestyle factors.35–38
Conclusions
Our results demonstrate that development of preeclampsia
increases the maternal risk of nonfatal or fatal coronary
events and CVD mortality later in life. The increased risk
associated with preeclampsia was observed both in mothers
with only 1 and in those with >1 lifetime pregnancies. In the
latter group, the increased risk for future adverse events was
not related to timing of preeclampsia in relation to parity (ie,
preeclampsia in the first versus preeclampisa in later
pregnancies). When associated with preterm delivery and/or
Table 3. Preeclampsia and Risk of Subsequent Major Coronary Events Among 342 421 Norwegian Women With 1 to 5 Singleton
Deliveries and a First Delivery During 1980–2002, Followed From the Age of 40
No./Events
Unadjusted Adjusted*
HR (95% CI) P Value HR (95% CI) P Value
All women (N=342 421)
No preeclampsia 323 323/857 1  1 
Preeclampsia only 12 592/64 2.05 (1.59–2.65) <0.001 2.02 (1.56–2.60) <0.001
Preeclampsia+SGA and/or preterm delivery† 6506/59 3.76 (2.88–4.89) <0.001 3.63 (2.79–4.72) <0.001
One lifetime pregnancy (n=61 352)
No preeclampsia 58 520/292 1  1 
Preeclampsia only 1663/19 2.36 (1.47–3.76) <0.001 2.26 (1.42–3.60) 0.001
Preeclampsia+SGA and/or preterm delivery 1169/19 3.56 (2.24–5.66) <0.001 3.32 (2.09–5.29) <0.001
More than 1 lifetime pregnancy (n=281 069)
No preeclampsia 264 803/565 1  1 
Preeclampsia complicating any pregnancy‡
Preeclampsia only 10 929/45 2.02 (1.49–2.73) <0.001 1.97 (1.45–2.67) <0.001
Preeclampsia+SGA and/or preterm delivery 5337/40 3.85 (2.79–5.31) <0.001 3.75 (2.72–5.17) <0.001
Preeclampsia complicating first pregnancy only
Preeclampsia only 6318/25 1.98 (1.33–2.96) 0.001 1.95 (1.31–2.91) 0.001
Preeclampsia+SGA and/or preterm delivery 2881/16 2.94 (1.79–4.83) <0.001 2.81 (1.70–4.61) <0.001
Preeclampsia complicating first and second pregnancies
Preeclampsia only 937/5 2.31 (0.96–5.58) 0.062 2.20 (0.91–5.32) 0.079
Preeclampsia+SGA and/or preterm delivery 826/8 4.43 (2.21–8.91) <0.001 4.66 (2.31–9.37) <0.001
Preeclampsia complicating second or later pregnancies
Preeclampsia only 3674/15 1.98 (1.19–3.31) 0.009 1.93 (1.16–3.23) 0.012
Preeclampsia+SGA and/or preterm delivery 1630/16 5.11 (3.11–8.39) <0.001 4.92 (2.99–8.10) <0.001
Cox regression analyses stratified by parity. HR indicates hazard ratio; SGA, small for gestational age (<10th percentile).
*Adjusted for education, marital status and birth year of first child.
†Preterm delivery (<37 weeks of gestation), SGA, or both.
‡The first time preeclampsia occurred, independent of which pregnancy.
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SGA babies, the risk of future adverse coronary events
associated with preeclampsia was even higher. Our findings
provide evidence in favor of monitoring these women who are
at increased risk for future coronary events.
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Table S1. Preeclampsia and Subsequent Risk of Major Coronary Events Among 504,623 Women With 1 to 5 Singleton Deliveries and a First 
Delivery During 1980–2002 After Exclusion of Women With a Diagnosis of Diabetes Mellitus*  
  Unadjusted  Adjusted† 
      
  No./Events HR (95% CI) P value  HR (95% CI) P value 
Major coronary event       
 No preeclampsia 475 160/1063 1 …  1 … 
 Preeclampsia only 19 417/83 2.07 (1.66–2.59) <0.001  2.05 (1.64–2.56) <0.001 
 Preeclampsia + SGA and/or preterm delivery‡ 10 046/76 3.68 (2.92–4.65) <0.001  3.58 (2.84–4.52) <0.001 
     Preeclampsia + SGA 4480/35 3.39 (2.42–4.75) <0.001  3.21 (2.29–4.49) <0.001 
     Preeclampsia + preterm delivery 3123/20 3.77 (2.42–5.87) <0.001  3.91 (2.51–6.09) <0.001 
     Preeclampsia + SGA + preterm delivery 2442/21 4.19 (2.72–6.45) <0.001  4.05 (2.62–6.24) <0.001 
 
Cox–regression analysis with preeclampsia as a time–dependent covariate. HR indicates hazard ratio; CI, confidence interval; SGA, small for 
gestational age (<10th percentile).  
* Diabetes mellitus occurring prior to first pregnancy. 
† Adjusted for education, marital status and birth year of first child. 








Table S2. Preeclampsia and Subsequent Risk of Major Coronary Events Among 506,397 Women With 1 to 5 Singleton Deliveries and a First 
Delivery During 1980–2002 With a Lower Cutoff Point for Small For Gestational Age and Preterm Delivery 
  Unadjusted  Adjusted† 
      
  No./Events HR (95% CI) P value  HR (95% CI) P value 
Major coronary event       
 No preeclampsia 476 506/1095 1 …  1 … 
 Preeclampsia only 22 815/114 2.39 (1.97-2.90) <0.001  2.36 (1.94-2.86) <0.001 
 Preeclampsia + SGA and/or preterm delivery‡ 7056/66 4.26 (3.32-5.46) <0.001  4.09 (3.19-5.25) <0.001 
     Preeclampsia + SGA 4886/41 3.59 (2.62-4.90) <0.001  3.41 (2.50-4.66) <0.001 
     Preeclampsia + preterm delivery 1265/15 6.77 (4.07-11.27) <0.001  6.96 (4.18-11.59) <0.001 
     Preeclampsia + SGA + preterm delivery 925/10 5.40 (2.89-10.07) <0.001  5.13 (2.75-9.57) <0.001 
 
Cox–regression analysis with preeclampsia as a time–dependent covariate. HR indicates hazard ratio; CI, confidence interval; SGA, small for 
gestational age (<7.5th percentile).  
† Adjusted for education, marital status and birth year of first child. 
‡ <34 weeks of gestation. 
 
 
